Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ASB3 in preparation of drugs for treatment of non-alcoholic fatty liver disease

A fatty liver disease, non-alcoholic technology, applied in the field of gene function, can solve the problem of less function of ASB3 gene, and achieve the effect of reducing fat accumulation, less side effects, and inhibiting content

Active Publication Date: 2019-11-22
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there are few related studies on ASB3 gene function, mainly focusing on GWAS analysis of the relationship between gene SNP and disease, for example, ASB3 may be related to bronchodilator responsiveness in asthma (Israel E, Lasky-Su J, Markezich A, et al. Genome -wide association study of short-acting beta2-agonists.A novelgenome-wide significant locus on chromosome 2 near asb3[J].Am J Respir CritCare Med,2015,191(5):530-537.Ortega VE.Predictive genetic profiles for beta-agonist therapy in asthma.A future under construction[J].Am J Respir CritCare Med,2015,191(5):494-496.Sordillo JE,McGeachie M,Lutz SM,etal.Longitudinal analysis of bronchodilator response in asthmatics and effect modification of age-related trends by genotype[J].Pediatr Pulmonol,2019,54(2):158-164.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ASB3 in preparation of drugs for treatment of non-alcoholic fatty liver disease
  • Application of ASB3 in preparation of drugs for treatment of non-alcoholic fatty liver disease
  • Application of ASB3 in preparation of drugs for treatment of non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] 1. Experimental method

[0044] 1. Tissue protein extraction:

[0045] The fresh tissue is taken and frozen at -80 degrees Celsius. Before extracting tissue protein, melt the powerful lysate and add PMSF. Weigh the tissue block, add 500ul of strong lysis solution for every 50 mg of tissue, and add 1ml of strong lysis solution for every 300 mg of adipose tissue. Add 2-3 small steel balls and oscillate on the tissue grinder at a frequency of 60 Hz for 120 seconds. After shaking, centrifuge at 14000g at 4°C for 5 minutes. The supernatant is taken as the tissue protein extract. According to the BCA quantification process, tissue protein quantification was performed.

[0046] 2. Oil red O staining: tissue & cells:

[0047] Tissue Oil Red O staining: Fresh tissues were taken and embedded in oct, and immediately frozen in liquid nitrogen. The frozen tissue was sliced ​​in a pre-cooled cryostat, cut into 12um thickness and immediately adhered to the anti-removal glass slide, and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of gene function, and in particular, relates to an application of an ASB3 gene in preparation of drugs for treatment of non-alcoholic fatty liver disease. The advantages comprise that by constructing an ASB3 gene fully knockout mouse model, the content of E3 ubiquitin ligase ASB3 in vivo can be inhibited, and the beta-oxidation and oxygen consumption of long-chain fatty acids can be enhanced, so as to reduce lipid accumulation in hepatocytes. The invention discloses new functions of the ASB3 gene and provides new targets and ideas for treatment of non-alcoholic fatty liver disease.

Description

Technical field [0001] The invention relates to the field of gene function, specifically, the discovery of new functions of the ASB3 gene, that is, the application of the ASB3 gene in the preparation of drugs for treating metabolic diseases. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) is a liver disease, which is related to visceral lipid accumulation and metabolic disorders, and it plays an increasingly important role in diseases that ultimately lead to liver fibrosis and liver tumors. . There are no accurate data on the incidence of NAFLD, but it is estimated that its global incidence is in the range of 28.01 / 1000 person-years to 52.34 / 1000 person-years; and the prevalence is about 25% (Younossi ZM, Koenig AB, Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.). Among them, the prevalence rate is 24.13% in North America, 30.45% in Sou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61P1/16
CPCA61K45/00A61P1/16
Inventor 杨冬琴刘杰张文丽吴梦梦何安芳
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com